The Global Migraine Therapeutics Market will be valued at USD 7 Billion in the year 2025, growing at a CAGR of 15.2% during the forecast period from 2016 to 2025. Migraine is a neurological disease, which involves nerve pathways and brain chemicals. The disorder causes severe recurring pain on one side of the head. Some of the common symptoms of migraines include nausea, sensitivity, and sensitivity to light and sound. There are various types of migraines, which are identified by their symptoms.
Usually, migraine can be episodic or chronic, depending on the period of headaches. Likewise, migraines mainly include four stages: Prodrome, Headaches, Aura, and Postdrome. Medications for migraine headaches can relieve the symptoms and pain of a migraine attack and also help avoid future attacks. Migraine treatment usually involves two types of drugs: preventive and abortive, depending on the intensity of a migraine attack.
The global migraine therapeutics market has grown significantly over the last few years. Several pharmaceuticals and biotech firms have introduced a number of preventative drugs and have upcoming products in the development stage. The global migraine therapeutics market is being mainly driven by factors such as rising female population, increasing expenditure on healthcare, economic growth, rapidly increasing cigarette consumption, growing prevalence of migraine, and unmet medical requirements. The new CGRP drugs will push the market growth in the future.
The increasing unmet patient needs have prompted many companies to initiate several research & development programs to introduce new molecules and develop generic formulations around the world. Besides, rising awareness about migraine therapeutics and development in the precise diagnosis of the condition will support the market growth over the next few years.
Increasing cases of migraine will drive the global migraine therapeutics demand. An increase in awareness will accelerate market growth. On the other hand, side effects related to migraine drugs will hamper the global market. On the contrary, the existence of growth opportunities in developing nations will offer new opportunities for the major players.
The growing prevalence of migraine enables the usage of more and more therapeutics for relief, and this will aid in driving the overall migraine therapeutics market. However, lack of proper treatment and undiagnosed cases, growing preference for alternative therapies, adverse effects of drugs, and generic penetration are some of the major factors that are hindering the global migraine therapeutics market.
Several firms such as the World health organization, American Headache & Migraine Association, and Indian Medical Association have undertaken efforts to grow awareness about migraines. They have launched programs, which are offering support to patients. An estimated 14–16% of people across the world suffer from Migraine disorder.
The global migraine therapeutics market is fragmented since the market has several companies offering varied therapeutics to treat migraine. By providing a complete analysis of the market’s competitive scenario and with information on products existing in the market, the analysis will help companies identify new growth opportunities and design new development strategies.
Global Migraine Therapeutics Market, By Drugs
In terms of drug type, Triptan is a new type of drug that raises serotonin levels in the brain, and constrict blood vessels and decrease inflammation, effectively ending a migraine attack. Likewise, Triptans make blood vessels constrict and block pain pathways in the human brain. The new innovative treatment and advances in medical science have led to the growth of this segment.
Global Migraine Therapeutics Market, By Geographical Regions
In terms of regional perspective, North America held the dominant share in the global market. It will maintain its position over the forecast period as well. Factors such as the increasing prevalence of migraine, growing adoption of novel therapeutics, and increasing target populations in the U.S. are some of the key factors that are helping the region to maintain its dominance.
As per the Migraine Research Foundation, in 2018, migraine is affecting 39 million women, men, and children in the United States and 1 billion across the globe. It has been found to be most common among people in the age group of 25 to 55 years. Hence, 12% of the population, comprising children suffer from migraines. All such factors are supporting North America’s dominance over the target market.
Key Market Developments
Some Key Findings of the Global Migraine Therapeutics Market Report:
Detailed scope covering all the major segments in the market
In line data validations to ensure data precision
Market recommendations supporting decision making processes
Round the clock analyst support to resolve your queries
Up to 15% additional free customization to meet your specific requirements